Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study

Journal of Bone and Mineral Research

Volumn 31, Issue 8, 2016, Pages 1527-1535

  Dempster, David W ^a,b   Roschger, Paul ^c   Misof, Barbara M ^c   Zhou, Hua ^a   Paschalis, Eleftherios P ^c   Alam, Jahangir ^d   Ruff, Valerie A ^d   Klaushofer, Klaus ^c   Taylor, Kathleen A ^d  

^a HELEN HAYES HOSPITAL   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d Lilly Corporate Center   (United States)

Author keywords

ANABOLICS; ANTIRESPORPTIVES; CLINICAL TRIALS; MATRIX MINERALIZATION; OSTEOPOROSIS

Indexed keywords

PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MATRIX; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; IMAGING; MAJOR CLINICAL STUDY; MORPHOMETRICS; OPEN STUDY; OSSIFICATION; OSTEOPOROSIS; QUANTITATIVE BACKSCATTERED ELECTRON IMAGING; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE;

EID: 84980048168     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2825     Document Type: Article

References (29)

1. Dempster DW, Zhou H, Recker RR, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012; 97(8):2799–808.
2. Dempster DW, Zhou H, Recker RR, et al. A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ Trial. J Bone Miner Res. 2016; DOI: 10.1002/jbmr.2804.
3. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008; 42(3):456–66.
4. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000; 15(2):183–7.
5. Fratzl P, Gupta HS, Paschalis EP, Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem. 2004; 14:2115–23.
6. Peterlik H, Roschger P, Klaushofer K, Fratzl P. From brittle to ductile fracture of bone. Nat Mater. 2006; 5(1):52–5.
7. Veenland JF, Link TM, Konermann W, Meier N, Grashuis JL, Gelsema ES. Unraveling the role of structure and density in determining vertebral bone strength. Calcif Tissue Int. 1997; 61(6):474–9.
8. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab. 2008; 26(1):1–8.
9. Kulak CA, Dempster DW. Bone histomorphometry: a concise review for endocrinologists and clinicians. Arq Bras Endocrinol Metabol. 2010; 54(2):87–98.
10. Roschger P, Gupta HS, Berzlanovich A, et al. Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32(3):316–23.
11. Misof BM, Dempster DW, Zhou H, et al. Relationship of bone mineralization density distribution (BMDD) in cortical and cancellous bone within the iliac crest of healthy premenopausal women. Calcif Tissue Int. 2014; 95(4):332–9.
12. Roschger P, Dempster DW, Zhou H, et al. New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res. 2007; 22(5):717–23.
13. Ruffoni D, Fratzl P, Roschger P, Phipps R, Klaushofer K, Weinkamer R. Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study. J Bone Miner Res. 2008; 23(12):1905–14.
14. Paschalis EP, Glass EV, Donley DW, Eriksen EF. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab. 2005; 90(8):4644–9.
15. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88(3):1150–6.
16. Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact. 2002; 2(6):538–43.
17. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001; 29(2):185–91.
18. Roschger P, Misof B, Paschalis E, Fratzl P, Klaushofer K. Changes in the degree of mineralization with osteoporosis and its treatment. Curr Osteoporos Rep. 2014; 12(3):338–50.
19. Roschger P, Lombardi A, Misof BM, et al. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). J Bone Miner Res. 2010; 25(1):48–55.
20. Zoehrer R, Roschger P, Paschalis EP, et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res. 2006; 21(7):1106–12.
21. Borah B, Dufresne TE, Ritman EL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006; 39(2):345–52.
22. Bala Y, Farlay D, Chapurlat RD, Boivin G. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol. 2011; 165(4):647–55.
23. Misof BM, Roschger P, Gabriel D, et al. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res. 2013; 28(3):442–8.
24. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int. 2007; 81(2):73–80.
25. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone. 2014; 67:246–56.
26. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18(11):1932–41.
27. Papapoulos SE. Use of bisphosphonates in the management of postmenopausal osteoporosis. Ann N Y Acad Sci. 2011; 1218:15–32.
28. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809–22.
29. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434–41.